Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Recursion Pharmaceuticals reports strong Q4 performance and strategic growth

Recursion Pharmaceuticals demonstrated robust financial performance, strategic partnerships, and technological advancements in its Q4 2024 earnings call. While facing challenges related to industry dynamics and funding uncertainties, the company is well-positioned to capitalize on opportunities for growth, innovation, and expansion in the biopharmaceutical sector.

Recursion Pharmaceuticals excels in Q1 with robust pipeline and AI focus

Recursion Pharmaceuticals reported a strong Q1 2025 performance, emphasizing strategic pipeline development and operational efficiency. Leveraging AI in drug discovery and partnerships, the company aims to lead in the industry while adapting to regulatory changes.

Recursion Pharmaceuticals reports robust Q2 performance and strategic growth plans

Recursion Pharmaceuticals (RXRX) showcased strong financial performance, innovative projects, and strategic partnerships in Q2 2025. While the company faces challenges in meeting partnership inflow targets and managing high-risk projects, opportunities abound in AI-driven research and collaborative ventures. Success hinges on effectively balancing financial sustainability with cutting-edge research initiatives and maintaining momentum in key development areas.

Recursion Pharmaceuticals excels in Q3, poised for growth under new CEO

Recursion Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2025, positioning the company for continued growth and innovation in the Tech-Bio sector. The leadership transition to Najat Khan as CEO, supported by a seasoned executive team, underscores a commitment to driving operational excellence, value creation, and sustainable growth. While facing challenges in cash management and operational efficiency, Recursion's focus on leveraging AI technology, expanding partnerships, and translating data into clinical proof presents promising opportunities for future success.

Recursion Pharmaceuticals excels in AI-driven innovation and operational efficiency

Recursion Pharmaceuticals demonstrated strong performance with positive milestones, cost reductions, and extended cash runway, leveraging AI for operational efficiency and innovation. The company's strengths in platform integration, diversified portfolio, and strategic pillars position it well for future growth and success in the biopharmaceutical industry. Challenges include regulatory engagement, operational scalability, and innovation alignment, while opportunities exist in partnerships, AI-driven discoveries, and therapeutic expansion for value creation.

Recursion Pharmaceuticals excels in Q1 with AI-driven innovations and pipeline advancements

Recursion Pharmaceuticals showcased strong clinical advancements, financial discipline, and pipeline progress in Q1 2026, positioning the company for sustained growth and innovation. The company's focus on AI-driven drug development, disciplined investment strategies, and leadership team enhancements underscore its commitment to long-term value creation and patient outcomes. While facing challenges in expense management and operational execution, Recursion's opportunities lie in leveraging AI capabilities, advancing pipeline candidates, and fostering strategic collaborations for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.